Trial · NCT00450619
Results by group164
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 164
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Stable Disease at 4 Months. | Arm A - EDTMP Alone | 2 | participants | ||
| Number of Patients With Stable Disease at 4 Months. | Arm B - 153Sm-EDTMP With Vaccine | 5 | participants | ||
| Progression Free Survival (PFS) | Arm A - EDTMP Alone | 1.7 | 95% Confidence Interval 1.3 to 2.3 | months | |
| Progression Free Survival (PFS) | Arm B - 153Sm-EDTMP With Vaccine | 3.7 | 95% Confidence Interval 2.4 to 4.7 | months | |
| Toxicity | Arm A - EDTMP Alone | 19 | Participants | ||
| Toxicity | Arm B - 153Sm-EDTMP With Vaccine | 22 | Participants | ||
| Number of Participants With Prostate-Specific Antigen (PSA) ≥ 30% | Arm A - EDTMP Alone | 0 | participants | ||
| Number of Participants With Prostate-Specific Antigen (PSA) ≥ 30% | Arm B - 153Sm-EDTMP With Vaccine | 4 | participants | ||
| Number of Participants With Prostate-Specific Antigen (PSA) ≥50% | Arm A - EDTMP Alone | 0 | participants | ||
| Number of Participants With Prostate-Specific Antigen (PSA) ≥50% | Arm B - 153Sm-EDTMP With Vaccine | 3 | participants | ||
| Overall Survival | Arm A - EDTMP Alone | 8.1 | 95% Confidence Interval 3.5 to 13.3 | Months | |
| Overall Survival | Arm B - 153Sm-EDTMP With Vaccine | 9.2 | 95% Confidence Interval 5.0 to 12.6 | Months | |
| Arm A: Prostate-Specific Antigen (PSA) T-cell Responses Post-vs. Pre-treatment | Arm A - EDTMP Alone | PT 11 (CD4) CD107a | 0 | Absolute # CD4 or CD8 producing cytokine | |
| Arm A: Prostate-Specific Antigen (PSA) T-cell Responses Post-vs. Pre-treatment | Arm A - EDTMP Alone | PT 11 (CD4) IFN-ϓ | 0 | Absolute # CD4 or CD8 producing cytokine | |
| Arm A: Prostate-Specific Antigen (PSA) T-cell Responses Post-vs. Pre-treatment | Arm A - EDTMP Alone | PT 11(CD4) IL2 | 0 | Absolute # CD4 or CD8 producing cytokine | |
| Arm A: Prostate-Specific Antigen (PSA) T-cell Responses Post-vs. Pre-treatment | Arm A - EDTMP Alone | PT 11 (CD4) TNF | 0 | Absolute # CD4 or CD8 producing cytokine | |
| Arm A: Prostate-Specific Antigen (PSA) T-cell Responses Post-vs. Pre-treatment | Arm A - EDTMP Alone | PT 11 (CD8) CD107a | 0 | Absolute # CD4 or CD8 producing cytokine | |
| Arm A: Prostate-Specific Antigen (PSA) T-cell Responses Post-vs. Pre-treatment | Arm A - EDTMP Alone | PT 11 (CD8) IFN-ϓ | 0 | Absolute # CD4 or CD8 producing cytokine | |
| Arm A: Prostate-Specific Antigen (PSA) T-cell Responses Post-vs. Pre-treatment | Arm A - EDTMP Alone | PT 11 (CD8) IL2 | 56 | Absolute # CD4 or CD8 producing cytokine | |
| Arm A: Prostate-Specific Antigen (PSA) T-cell Responses Post-vs. Pre-treatment | Arm A - EDTMP Alone | PT 11 (CD8) TNF | 186 | Absolute # CD4 or CD8 producing cytokine |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00450619/results